

KIT N. SIMPSON Dr.P.H.
Department of Health Administration and Policy
College of Health Professions
Medical University of South Carolina

151 Rutledge Avenue, Bldg B
P.O. Box 250807
Charleston S.C. 29425

Phone (843) 792-0760, FAX (843) 792-3327
Email: simpsonk@musc.edu

EDUCATION

Johns Hopkins University, School of Hygiene and Public Health, 1991 Faculty Fellow; Health Care Finance (Economic Evaluation and Outcomes Research)

University of North Carolina at Chapel Hill, School of Public Health, 1988, Dr.P.H.; Health Policy and Administration (Health Services Research)

University of North Carolina at Chapel Hill, School of Public Health, 1983, MPH; Health Policy and Administration (Financial Management)

Hospitalslaborantskolen, Copenhagen and Slagelse Centralsygehus (Central Hospital), Denmark 1965-68. Diploma Medical Technology

Pitman School of Business and Kings College, London University, England 1964; English and English Literature

Slagelse Handelsskole, Slagelse, Denmark 1961-64; Diploma in Business Administration; Marketing and Merchandizing

PROFESSIONAL ACTIVITIES

- 2005-present** Professor, Department of Health Administration and Policy, and Director of Outcomes Research Program, Center for Health Economics and Policy Studies, College of Health Professions; Professor of Pharmacy and Clinical Sciences, College of Pharmacy; Professor of Biostatistics, Bioinformatics, and Epidemiology, College of Medicine; Investigator, Center for Health Economics and Policy Studies and Hollings Cancer Center. Medical University of South Carolina, Charleston, S.C.
- 2004-2005** Interim Associate Dean for Research and Professor of Health Administration & Policy, College of Health Professions; Professor of Pharmacy and Clinical Sciences, College of Pharmacy; Professor of Biostatistics, Bioinformatics, and Epidemiology, College of Medicine; Investigator, Center for Health Economics and Policy Studies. Medical University of South Carolina, Charleston, S.C.
- 2000-2004** Professor and Vice Chair for Research, Department of Pharmacy Practice, College of Pharmacy; Professor of Biometry & Epidemiology, College of Medicine; Professor of Health Administration & Policy, College of Health Professions; Senior Investigator, Center for Health Economics and Policy Studies. Medical University of South Carolina, Charleston, S.C.
- 1998-2000** Professor, Faculties of Pharmacy and Health Administration & Policy, and Investigator, Center for Health Care Research, Medical University of South Carolina, Charleston, S.C.
- 1985-98** Associate Professor (with tenure), and Assistant Professor 1985-95, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC (on leave 1997/98).

- 1997-98** Director, Health Economics Research, Chiron Corporation, Emeryville CA, and Director of Clinical Epidemiology/Economics, Chiron Informatics, Alameda CA.
- 1996-97** Associate Professor of Pharmacoeconomics, Center for Health & Social Policy, School of Business and Economics, University of Odense, Denmark.
- 1991-97** Visiting Research Scientist for Modeling Studies, Battelle MEDTAP and MEDTAP International, Arlington, VA.
- 1985-89** Director of Executive Master's Programs (Clinical Assistant Professor). Health Policy and Adm., School of Public Health, UNC.
- 1980-85** Director of Allied and Public Health Education, Mountain Area Health Education Center (AHEC), Asheville, NC and Adjunct Assistant Professor, UNC School of Medicine.
- 1978-80** Program-Coordinator, The Health Adventure, Asheville, NC.
- 1979** Instructor. Medical Practice Management Curriculum. Cecil's Jr. College, Asheville NC.
- 1976-78** Practice Manager, G.A. Simpson, M.D., and Associates, Asheville, NC. Occupational Medicine.
- 1972** Clinical Services Manager, Herbert Simpkins, M.D., Irvington, N.J.
- 1969-71** Chief Research Technologist, Division of Nephrology, Cornell Medical College, N.Y.
- 1968** Laboratory Supervisor, Central Laboratory and Bloodbanking, Lasarettet Hospital, Gaellivare, Sweden.
- 1968** Staff Medical Technologist, Slagelse Central Sygehus, Slagelse, Denmark.

Honors:

Scholar of the Year. MUSC College of Health Professions 2007.
 Collaborating Faculty Scholar Award, MUSC Physician Assistant Program August 2006.
 Health Care Management Research Award. American College of Healthcare Executives, 1991
 The Robert Wood Johnson Foundation Faculty Fellowship in Health Finance, 1991-93
 Distinguished Scholar in Allied Health, Albany State College, Albany, Georgia, 1985
 Public Health Service Traineeship, 1984-1986
 Delta Omega Graduate Public Health Honor Society, 1983

Boards and Committees:

Member of the Editorial Board for the peer-reviewed journal: Clinical Medicine & Research 2007

NIAID, National Institute of Health. Member, Special Emphasis Grant Review Panel: AIDS Clinical Research Network. 2006, 2007

American Cancer Society Pilot Study Grant Proposal Reviewer. Hollings Cancer Center. 2005, 2006, 2007

NCI P01 Program. Special emphasis panel grant reviewer: 2006, 2007, 2008

Netherlands Board of Health Research and Development; proposal reviewer for prevention proposals 2008.

Member MUSC IRB, January 2007- December 2010.

Member, MUSC Advisory Committee for NIH T32 Pre-doctoral Training Roadmap grant. 2006-present

Co-Chair for Study Design and Statistical Methods workgroup for the MUSC Clinical and Translational Science Award.

Member MUSC T20 Translational Research Fellowship Advisory Group. 2007- present.

Member, CHP Research Council. 2006- present.

Planning Consortium Member, 1999-2000 for the Tri-national Trial of Options in Management with Antiretrovirals (OPTIMA), and Member Health Economics Core for the UK component of OPTIMA. 2000-2005.

Expert Panel. Traumatic Brain Injury Rehabilitation, NIH Consensus Conference. August 1997 to October 1998.

HIV/AIDS Economics Review Group. Cochran Collaboration, San Francisco 1998.

MPH Degree Development Commission. Universities of Copenhagen, Aarhus and Odense, Denmark 1996-97.

Scientific Committee. First European Conference on the Economics of Cancer. European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. 1997.

Scientific Committee. Second European Conference on the Economics of Cancer. EORTC, Brussels, Belgium. 2000.

AIDS Economics Research Collaboration, London, United Kingdom 1996-2000.

Information Systems Development and Research Committee, Kobler Center, Chelsea and Westminster Hospital, London England. 1995-98.

UNC School of Public Health, Department of Health Policy and Administration: Doctoral Program Advisory Committee 1988-98; Academic Standards/Curriculum Committee, 1988-91; Strategic Directions Committee, 1985-86; Executive Committee 1986-88; Committee for Development of Award for Excellence in Health Administration 1984, 1986; Advisory Committee on Non-Residential Programs, 1984

UNC School of Public Health Institutional Review Board, 1995-1997.

Committee to review Dean Michel Ibrahim for re-appointment, 1991.

UNC Faculty Council member 1990-93

Theta Chapter, Delta Omega Graduate Public Health Honor Society. President 1993-94. Treasurer 1989-91, Secretary 1991/92, Vice President 1992-93

Advisory Committee on Primary Care Institutes, National Association of Community Health Centers 1993

American Public Health Association, Chair of Health Administration Section 1991-93; Chair of Quality Management Committee; Governing Council Member 1987-89; Section Council Member, 1983, 1984-87; Policy Development Committee 1986, 1987, 1988, 1989, 1990; Chair of Scientific Program Committee, 1986; member 1983, 1984, 1987;

North Carolina Hospital Association, DRG Education Committee, 1983

Reviewer for the following journals: JAMA; AIDS; JAIDS; AIDS Care; AIDS Research and Therapy; Health Economics; PharmacEconomics; Value in Health; Disease Management & Health Outcomes; Medical Care; CRMO; American J. of Public Health; Hospital & Health Services Administration; J. of Health Services Research; J of Preventive Medicine; J. of Urology; National Journal of Medicine; J of Rheumatology.

REFEREED PUBLICATIONS

- 80 Hayslip JW, **Simpson KN**. Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65-70 Years with Follicular Lymphoma in Second Remission. *Clinical Lymphoma & Myeloma*. 8(3) 2008.
- 79 **Simpson KN**, Roberts G, Hicks CB, Finnern HW. Cost-effectiveness of Tiplranavir in Treatment Experienced HIV Patients in the US. *HIV Clinical Trials*. in press.
- 78 **Simpson KN**, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov Model and Discrete Event Simulation (DES) Techniques for HIV Disease. *Pharmacoeconomics* in press.

- 77 Kirbach S, **Simpson KN**, Nietert PJ, Mintzer JE. A Markov model of the cost-effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. *Clinical Drug Invest.* 2008 28(50):291-303.
- 76 Clancy DE, CE Dismuke, KM Magruder, **KN Simpson**, WD Bradford. Do Group Visits Lead to Lower Costs of Diabetes Care? *Am. J. Managed Care.* 2008 Jan; 14(1):39-44.
- 75 Bushard RL, Massey EB, Simpson TW, Arial JC, **Simpson KN**. Poly-pharmacy: Misleading but manageable. *Clinical Interventions in Ageing.* 2008 ; 1-9.
- 74 **Simpson KN**, Walter J. Jones, Rukmini Rajagopalan, Birgitta Dietz. Cost-effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France Italy and Spain. *Clin. Drug Invest.* 2007 27(12): 807-817.
- 73 Hubben JA, Bos JM, Veltman-Starkenburger CA, Stegmeijer S, Finnern HW, Kappelhoff BS, **Simpson KN**, Tramarin A, Postma MJ. Cost-Effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. *Cost Effectiveness and Resource Allocation* 2007 5:15; 1-9.
- 72 Mauldin PD, **Simpson KN**, Palesch YY, Spilker JS, Hill MD, Broderick JP, and the IMS III Investigators. Design of the Economic Evaluation for the Interventional Management of Stroke Trial. *Int. J. Stroke* 2008; 3(2): 138-144.
- 71 Lunsford SL, **Simpson KS**, Chavin KD, et al. Can Family Attributes Explain the Racial Disparity in Living Kidney Donation? *Transplant Proceed* 2007 39(5): 1376-80.
- 70 **Simpson KN**, Walter J. Jones, Rukmini Rajagopalan, Birgitta Dietz. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir plus ritonavir in antiretroviral-experienced patients in the U.S.: Modeling the combined effects of HIV and Heart Disease. *Clin. Drug Invest.* 2007 27(7): 443-452.
- 69 **Simpson KN**, Luo MP, Chumney ECG, Mazyck J, King M, Brun S, Ashraf T. Cost Effectiveness of Lopinavir/r vs. Atazanavir in Treating Antiretroviral-Naïve Patients: Modeling the Combined Effects of HIV and Heart Disease. *Clin. Drug Invest.* 27(1):67-74, 2007.
- 68 Moeller KE. Barnes BJ. Stanley KM. Worrall CL. Lunsford SL. **Simpson KN**. Miller JG. Spencer AP. Compliance of an institution-specific alcohol withdrawal protocol with evidence-based practice guidelines. *Pharmacotherapy.* , 2006 26(3):445-6.
- 67 Lunsford SL, **Simpson KS**, Chavin KD, et al. Racial Disparities in Living Kidney Donation: Is There a Lack of Willing Donors or an Excess of Medically Unsuitable Candidates? *Transplantation* 2006; 82(7): 876-881.
- 66 Okonofua EC, **Simpson KN**, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic Inertia Is An Impediment To Achieving The Healthy People 2010 Blood Pressure Control Goals. *J Hypertension*, 47(3):345-51, 2006.
65. Chumney ECG, Mauldin PD, **Simpson KN**. Charges for Hospital Admissions Attributable to Health Disparities for African American Patients in South Carolina During 1998-2002. *JNMA* 2006 98:5;690-95.
64. Taylor L, **Simpson K**, Bushard R, Reeves CB, Elkin TD, Fortson BL, Boll T, Patell S. Insurance barriers among childhood survivors of pediatric brain tumors: The case for neurocognitive evaluations. *J. Ped. Neurosurgery* 42(4):223-7, 2006.
63. Lunsford SL, **Simpson KN**, Chavin KD, Hildebrand RG, Miles LG, Shilling LM, Smalls GR, Baliga PK. Racial differences in coping with the need for kidney transplantation and willingness to ask for live organ donation. *Am. J. Kidney Dis.* 47(2):324-31, 2006 .
62. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, **Simpson K**. Sertraline in the Treatment of Co-occurring Alcohol Dependence and Posttraumatic Stress Disorder. *Alcoholism: Clinical and Experimental Research* 29(3):395-401, 2005.

61. Book SW, Boehm RS, **Simpson KN**. Treating Alcoholics With a Co-Occurring Anxiety Disorder: A Markov Model to Predict Long Term Costs. *Dual Diagnosis* 2005 1(4);53-62.
59. Stanley KM, Spencer AP, Lunsford SL, **Simpson KN**, Miller JG, Worrall CL. Experience with an Adult Alcohol Withdrawal Syndrome Practice Guideline in Internal Medicine Patients. *Pharmacotherapy* 2005, (25)8.
58. **Simpson KN**, Luo MP, Chumney ECG, Sun E, Brun S, Ashraf T. Cost effectiveness of using lopinavir vs. nelfinavir as the first highly active antiretroviral therapy regimen for HIV infection. *HIV Clinical Trials* 2004 (5)5;294-304.
57. McBurney PG, **Simpson KN**, Darden PM. Potential cost savings of decrease emergency department visits through increased continuity in pediatric medical home. *Am Peds* 2004 4(3):204-8.
56. Chumney ECG, Biddle AK, **Simpson KN** et al. The effect of cost construction based on either DRG or ICD-9 codes or risk-group stratification on the resulting cost-effectiveness ratios. *J Pharmacoeconomics* 2004 22(18); 1209-16.
55. Killeen, TK, Brady, KT, Gold, P, **Simpson, K**, Tyson, C. Comparison of self-report and archival data abstraction of service utilization in a community sample of treatment seeking alcohol abusing individuals. *Drug and Alcohol Dependence* 2004;73:141-147.
54. Kozel FA, George MS, **Simpson KN**. Decision analysis of cost effectiveness of repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for treatment of non-psychotic severe depression. *CNS Spectrums* 2004 9(6):476-82.
53. Stanley KM, Amabile CM, **Simpson KN**, Couillard D, Norcross ED, Worrall CL. Impact of an alcohol withdrawal syndrome practice guideline on patient outcomes in the acute care setting. *PharmacoTherapy* 2003(23)7;843-54.
52. Siachos AT, Van Bakel A, Feldman D, Uber W, **Simpson KN**, Pereira N. Silent strokes in patients with heart failure. *J of Cardiac Failure*. 11(7):485-9, 2005.
51. Highland KB, Strange C, Mazur J, **Simpson KN**. Treatment of pulmonary hypertension: A decision analysis. *Chest* 2003 124(6):2087-2092.
50. Egede LE and **Simpson KN**. Epidemiology, treatment and costs of depression in adults with type-2 diabetes. *Expert Rev. Pharmacoeconomics Outcomes Res.* 2003 3(3) 89-100.
49. Egede LE, Zheng D, **Simpson K**. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. *Diabetes Care* 2002 25(3) 464-470.
48. Richter A, Hauber B, **Simpson K**, Mausekopf JA, Yin D. A Monte Carlo simulation for modeling outcomes of AIDS treatment regimens. *PharmacoEconomics* 2002 20(4):215-224.
47. Brady KT, Sonne SC, Malcolm R, Randall CL, Dansky BS, **Simpson K**, Brondino M. Carbamazepine in the treatment of cocaine dependence: Subtyping by affective disorder. *Experimental & Clinical Psychopharmacology*. 2002;10(30):276-285.
46. Chumney ECG, **Simpson KN**. The emerging role of the consumer in pharmaceutical pricing decisions. *Disease Management and Health Outcomes* 2001 (10) 2;1-4.
45. **Simpson KN**, Voit EO, Goodman R, Chumney ECG. Estimating the social and economic benefits of pharmaceutical innovations: Modeling clinical trial results in HIV-disease. *Research in Human Capital and Development* 2001 (14) 175-198.
44. Marshall DA, **Simpson KN**, Earle CC, Chu CW. Economic decision analysis model of screening for lung cancer. *Eur J Cancer* 2001 (37) 1759-1767.

43. Marshall DA, **Simpson KN**, Earle CC, Chu CW. Potential cost effectiveness of one-time screening for lung cancer in a high-risk cohort. *Lung Cancer* 2001 32(3) 227-236.
42. Youle M, Holzer C, **Simpson KN**, de Clerq K, Miller V. HIV-1 drug resistance testing: Health outcomes. *Antiviral Therapy* 2000, 5(2):113-115.
41. Helm, JF, Russo MW, Biddle AK, **Simpson KN**, Ransohof DF, Sandler RS. Effectiveness and economic impact of a concerted effort to implement mass fecal occult blood screening. *Am J Gastroenterology* 2000 95(11):3250-3258.
40. Mauskopf JA, Tolson JM, **Simpson KN**, Pham SV, Albright J. The impact of zidovudine-based triple combination therapy on an AIDS drug assistance program *JAIDS*, 2000; 23:302-313.
39. Biddle AK, **Simpson KN**. Clinical benefits, budget impacts, and cost effectiveness of managing HIV+ patients with triple combination therapies in five countries. *Value in Health* 2000; (3)3 186-201.
38. Marshall D, **Simpson KN**, Martinot M, McHutchison J, Perrillo R, Marcellin P, Banach M, Pawlotsky J-M. Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy. *J. Drug Assessment*, 2000; 3:47-62.
37. McLaughlin, CP, **Simpson, KN**. Operations management theory and the management of medical technology. *Int. J. Healthcare Technology and Management*, 2000 2(1/2/3/4) 181-203.
36. Marshall DA, **Simpson KN**, Norton EC, Biddle AK, Youle M. Measuring the Effect of Clinical Guidelines on Patient Outcomes. *Intl. J. Technology Assessment in Hlth. Care*, 2000 3(1) 47-63.
35. Ragnarson KT, Moses LG, Clarke WR, Daling JR, Garber SL, Gustafson CF, Holland AL, Jordan BD, Riddle MA, Roth EJ, Seltzer MM, **Simpson KN**, Small SL, Therrien B, Wexler BE Yawn BP. Rehabilitation of persons with traumatic brain injury. *JAMA* 1999, 282(10):997-983.
34. Shih YCT, Kauf TL, Biddle AK, **Simpson KN**. Incorporating problem-based learning into a lecture-based pharmacoeconomics course. *Am. J. of Pharmaceutical Ed.* 1999, Vol 63, Summer 152-159.
33. Biddle AK, **Simpson KN**. Modeling the cost effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom. *J. Medical Economics* 1999; 2: 85-105.
32. Youle M, Trueman P, **Simpson K**. Health economics in HIV disease. *PharmacoEconomics* 1998 14 (supl 4);1-12.
31. Neymark N, W Kiebert, K Torfs, P Fayers, R Gelber, G Guyatt, B Hillner, P Kind, D Machin, E Nord, D Osoba, D Revicki, K Schulman, **K Simpson**. Methodological and statistical issues of Quality of Life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop. *European J of Cancer* 1998 34(9):1317-1333.
30. Mauskopf J, Lacey L, Kempel A, **Simpson KN**. The cost effectiveness of treatment with Lamivudine and Zidovudine compared to Zidovudine alone: A comparison of Markov model and trial data estimates. *Am J Managed Care* 1998 4(7):1004-1012.
29. Myers ER, Thompson JW, **Simpson KN**. Mandatory versus voluntary screening of pregnant women for human immunodeficiency virus: a cost-effectiveness analysis. *Obstetrics & Gynecology* 1998, 91(2):174-181.
28. Halperen M, Palmer CS, **Simpson KN** et al. The marginal cost effectiveness of using three laboratory test production processes for the management of cardiac surgery patients in intensive care units. *Am J Medical Quality* 1998 13(1):3-12.
27. **Simpson KN**, Coughlin M, Eron J, Bussell J. Idiopathic Thrombocytopenia Purpura: Treatment patterns and an analysis of costs associated with intravenous immunoglobuline (IVIG) and anti-D therapy. *Seminars in Hematology* 1998, 35(S1):58-64.

26. Portela M, **Simpson KN**, Guess H, Sen PK, Kilpatrick K. Markers and cofactors for progression of patients with HIV+ disease. *J Mem Inst Oswaldo Cruz*, 1997 92(4):437-457.
25. Almasdottir AB, Hartzema AG, Bush PJ, **Simpson KN**, Zimmer C. Children's attitude and beliefs about illness and medicines. *J Soc. Adm. Pharmacy* 1997 14:1 26-39.
24. Chancellor J, Hill A, **Simpson K**, Yule M. Cost effectiveness of 3TC and ZDV in patients with HIV-Disease. *PharmacoEconomics* 1997 12:1 1-13.
23. Shugars DA, Benson K, White RP, **Simpson KN**, Bader JD. Developing a measure of patient perceptions of short-term outcomes of third molar surgery. *J Oral Maxillofac Surg* 1996 54: 1402-1408.
22. McLaughlin CP, **Simpson KN**. The new realities in health care technology assessment in U.S. institutions. *Intern. J. Technology Management* 15(3-5):507-521, 1998 .
21. **Simpson KN**. Design and assessment of cost effectiveness studies in AIDS populations. *JAIDS* 1995 Vol 10 Supp.4 S28-S32.
20. Zarkin GA, Bala MV, Wood LL, Bennett CL, **Simpson KN**, Dohn MN. Estimating the Cost-Effectiveness of Atovaquone versus Intravenous Pentamidine in the Treatment of Mild- to Moderate-PCP Patients. *PharmacoEconomics* 1996 9:6 525-534.
19. **Simpson KN**. Modeling with clinical trial data: Getting from the data researchers have to the data decision makers need. *Drug Information J.* 1995 29:4 1431-1440.
18. Revicki, D.A., **K.N. Simpson**, A.W. Wu and R.L. LaVallee. Quality of Life in Rifabutin Prophylaxis for Mycobacterium Avium Complex in Persons with AIDS. *Quality of Life Research* 1995 Vol 4 309-318.
17. DesHarnais SI and **Simpson KN**. Antiviral drug use in hospitalized patients with herpes infections: Variations in practice patterns. *Am J Medical Quality* 1996 11:1, 33-42.
16. **Simpson KN**, King C, Lynch S, Rentz A, Stevens C. Cost of Ultrasound Screening in Low-Risk Pregnancies. *J Mater Fetal Invest* 1995 5 175-177.
15. **Simpson K.N.** and Lynch S.R. Cost savings from the use of antenatal steroids to prevent respiratory distress syndrome and related conditions in premature infants. *Am J Obstet Gynecol* 1995; 173:316-21.
14. **Simpson, K. N.**, A. Biddle, NR Rabinivich. A Model for Estimating the Impact of Changes in Children's Vaccines. *Am J Pub Hlth* 1995 85:12 1666-1672.
13. Luce, B.R. and **K.N. Simpson**. Methods of Cost Effectiveness Research: Areas of Consensus and Debate. *Clinical Therapeutics* 1995 17:1 109-125.
12. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola R Zellinger J and **Simpson KN**. Health Care Expenditures for Tuberculosis in the United States. *Arch Intern Med* 1995 155 1595-1600.
11. **Simpson K.N.** Problems and Perspectives on the Use of Decision-Analysis Models for Prostate Cancer. *J Urology* 1994, 152; 1888-1893.
10. **Simpson K.N.** Outcomes research in prostate cancer- Editorial. *J Urol* 1994, 152; 1865.
9. Knechten, H nach **KN Simpson**. Argumente Fur die Kombination von Azidothymidin und Zalcitabin. Springer: *Belage fur Internisten*, pp 17-18, 1994.
8. **Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. Cost Effectiveness of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients with CD4 counts ≥ 300 per mm^3 in Five European Countries. *PharmacoEconomics* 1994, (6)6; 553-562.

7. LaVallee, RW and **Simpson, KN**. Working for the Government: PAs in the Department of Veterans Affairs. *J Am Acad Physician Assist*, 1993, 6:2 135-9.
6. Kaluzny, AD, CP McLaughlin, and **KN Simpson**. Applying Total Quality Management Concepts in Public Health Organization. *Public Health Reports*, 1992, 257-264.
5. **Simpson, K.N.**, G. Stoodt, S.G. Sherman, and P. Rochester. Strategic Planning for Public Health: Cancer Control in North Carolina. *Evaluation and Program Planning: Int J*, 1992, Vol 15, pp 383-393.
4. DesHarnais, SI and **KN Simpson**. Indices for Monitoring Hospital Outcomes in Developed Countries. *Health Policy*, 1992, Vol 21, pp 1-15.
3. **Simpson, K.N.** and Lyle B. Snider. Informing Mammography Coverage Debate: Results of Meta Analysis, Computer Modeling, and Issue Analysis. *Intl J Tech Ass Hlth Care*, 1991, Vol 7, No. 4, pp 616-631.
2. **Simpson, KN**, AD Kaluzny, and CP McLaughlin. Total Quality and the Management of Laboratories. *Clin Lab Mgt Rev*, 1991, pp 448-462.
1. **Simpson, K.N.** and J.E. Veney, "National Indicators for Health for All," *Soc Indicators Res*, Oct. 20, 1988, pp. 533-548.

Dissertation

Simpson, K.N., Analyzing the Effect of Public Prevention Programs on Low Birth Weight in North Carolina Counties." Doctoral Dissertation, 1988.

Book Chapters

Simpson KN and McLaughlin CP. "Strategic Decision Making, Economic Analysis, and TQM" in McLaughlin, C.P. and A.D. Kaluzny (eds.), *Continuous Quality Improvement in Health Care*, Second Edition. Gaithersburg, MD: Aspen Publishers Inc., 1999.

McLaughlin CP, **Simpson KN**. *Operations Management Theory and the Management of Medical Technology* 37 pp, forthcoming

Simpson KN and McLaughlin CP. "Strategic Decision Making, Economic Analysis, and TQM". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 148-166.

Simpson KN, McLaughlin CP, and Kaluzny AD. "Planning, Organizing, and Leading Continuous Improvement". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 169-186.

Simpson KN, Kaluzny AD, and McLaughlin CP. "Total Quality and the Management of Laboratories". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 265-276.

McLaughlin, CP and **Simpson, KN**. "Does TQM/CQI Work in Health Care?". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 33-46.

Kaluzny AD, McLaughlin CP, and **Simpson KN**. "Applying Total Quality Management Concepts to Public Health Organizations". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 277-287.

McLaughlin CP and **Simpson KN**. "Holston Valley Hospital and Medical Center: Case 2". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 335-360.

Simpson KN, DesHarnais SI, Jacobs A, and Menapace A. " Methods for Defining Medical Service Areas". In Geographic Methods for Health Services Research. Eds. Ricketts TC, Savitz LA, Gesler WM, and Osborne ON. Lanham, MD: 1994, pp 207-233.

REPORTS and MONOGRAPHS

KN Simpson, EG Chumney, AC Simpson. Predicting High Cost for Schizophrenia Patients on Medicaid. Report to Comprehensive NeuroScience, Inc. August 8, 2004

Riesebrugh N, **Simpson KN**. Economic evaluation of lopinavir/ritonavir in the treatment of human immunodeficiency virus. Final Report 2-23-2001. The HOPE (Health Outcomes and PharmacoEconomics) Research Centre, University of Toronto, ON m4n 3M5.

Report of the Panel for Consensus Development Conference on Rehabilitation of Persons with Traumatic Brain Injuries. National Institutes of Health, Bethesda MD, October 26-28, 1998.

Biddle AK, **Simpson KN**. Pediatric Allergy Learning Study (PALS): An evaluation of the effects of Claritin on seasonal allergic rhinitis-associated emotional and school performance impairments in children who are at least 7 and less than 11 years of age: An outcomes study. ACER/Excel and Schering Corp. December 1998.

Consortium for Spinal Cord Medicine. Prevention of Thromboembolism in Spinal Cord Injury. Clinical Practice Guidelines for Spinal Cord Medicine. Paralyzed Veterans of America, Washington DC, February 1997.

Consortium for Spinal Cord Medicine. Acute Management of Autonomic Dysreflexia: Adults with Spinal Cord Injury Presenting to Health Care Facilities. Clinical Practice Guidelines for Spinal Cord Medicine. Paralyzed Veterans of America, Washington DC, February 1997.

Committee on Guideline Development. Standards for the Development of Practice Guidelines in VA Health Systems V.A. Institute for Quality Management, Durham, N.C. 1996.

Simpson KN. A Strategic Model for Predicting Cost Effectiveness of Drug X to Inform Phase I Trial Decisions. Confidential Client. Jan. 1, 1996.

Simpson KN, Iztler R. Exploratory Economic Analysis of Data from Randomized Clinical Trials of Antiretroviral Therapy in HIV Disease Populations and Recommendations for Future Study Design and Analysis Protocols. Confidential Client. March 5, 1996.

Simpson KN. Costs and Expected Health Outcomes from the First Year of Inivrase Combination Therapy in Canada with Cost Estimates for Individual Provinces. Report to Hoffman-La Roche Limited, Toronto Canada. February 27, 1996.

Simpson KN, LaVallee RL, Portela M. Outcomes and Costs of Monotherapy with AZT vs. Combination Therapy with Saquinavir and ddC in U.S. Patients with HIV-Disease. Report to Roche Laboratories, Nutley NJ. Department of Health Policy and Administration, UNC School of Public Health. January 20, 1996.

Simpson KN, Coughlin C, LaVallee RL, Branthwaite D, Calhoun E. Cost Comparisons of IVIG and WinRho and Treatment Patterns for Patients with ITP. MEDTAP International Inc. Arlington VA. December 29, 1995.

Simpson KN, Flepp M, Hirschel B. Cost and Consequences of Adding Inivrase to Current Antiviral Therapy for Swiss Patients. MEDTAP International, Arlington VA. December 27, 1995.

Simpson KN, Luce BR. Types and uses of cost-effectiveness studies. Background paper. State-of-the-art conference: Technology Assessment: A Tool for Technology Management and Improved Patient Outcomes. VA Office of Research and Development and Foundation for Health Services Research. Washington DC. Jan. 1995.

Simpson, KN and RL LaVallee. Technical Effectiveness and Economic Efficiency of Point-of-Care Testing for Critically Ill Patients: GEM Premiere versus Usual Laboratory Testing Procedures. P24838. Arlington VA, Battelle Medical Technology and Policy Research Program, 1994

Brown R, Palmer CS and **Simpson KN**. The Cost of Tuberculosis in the United States in 1991. Final report to Centers for Disease Control and Prevention. Battelle Medical Technology and Policy Research Center, 1994.

Simpson, K.N., C. King, S.R. Lynch, A. Rentz and C. Stevens. Cost of Ultrasound Screening in Low-risk Pregnancies. Final report to the National Institute of Child Health and Development 1994.

Simpson, K.N., S.R. Lynch, F.E. Mebane, T.J. Hamby and C. Paramore. Cost Effectiveness of the Use of Antenatal Steroids to Prevent Respiratory Distress Syndrome and Related Conditions in Premature Infants. Final report to the National Institute of Child Health and Development 1993.

Simpson, Kit N. and R. L. LaVallee. Cost Effectiveness of Using Rifabutin for the Prevention of Mycobacterium Avian Complex (MAC) Bacteremia in AIDS Patients with CD4 <200 per mm³ in the United Kingdom. Washington, DC: Battelle Medical Technology and Policy Research Center, 1993.

Luce, Bryan and **Kit N. Simpson**. Methods of Cost Effectiveness Research: Areas of Consensus and Debate. Report to the Pharmaceutical Manufacturers Association. Washington, DC: Battelle Medical Technology and Policy Research Center, 1993.

Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in Italy with CD4 counts 300 per mm³. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1993.

Simpson, Kit N., A. Biddle and D. Boldy. A Model for Estimating the Impact of Research Investment Choices for the Children's Vaccine Initiative. Final Report of Phase I. National Institutes of Health order No. 263-MD-14293, 1993.

Simpson, Kit N., and Ruth E. Brown. Cost Effectiveness of Prostate Specific Antigen and Digital Rectal Examination in the Detection of Prostate Cancer. Washington, DC: Battelle Medical Technology Assessment and Policy Research Centre, 1993.

Simpson, Kit N. and Rebecca L. LaVallee. Cost Effectiveness of Using Rifabutin for the Prevention of Mycobacterium Avian Complex (MAC) Bacteremia in AIDS Patients with CD4 <200 per mm³. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1993.

Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients with CD4 Counts 300 per mm³: Base Model and Switzerland. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for German AIDS Patients with CD4 Counts 300 per mm³. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in France with CD4 counts 300 per mm³. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in the United Kingdom with CD4 Counts 300 per mm³. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

Veney, JE, KN **Simpson**, and JC Jacobson. Evaluation Design for Community Programs for Clinical Research in AIDS Final Report Submitted to the Community Clinical Research Branch, Division of AIDS, NIAD August 27, 1991.

Veney, JE, **KN Simpson**, and JC Jacobson. Cost Analysis for the Evaluation Design for Community Programs for Clinical Research in AIDS. Community Clinical Research Branch, Division of AIDS, NIAD October 18, 1991.

Simpson, K.N. and K.E. Kilpatrick. Final Report on the Reevaluation of the Florida Demonstration Project REACH: Rural Efforts to Assist Children at Home. Report to The Robert Wood Johnson Foundation, June, 1990.

DesHarnais, S. and **K. Simpson**. Small Area Variations in Utilization and Outcomes for Hospital Care Among Medicare Beneficiaries: Results of Analysis for North Carolina. August 1989.

Simpson, K. and L. Snider. Cost Effectiveness of Mandating Third Party Reimbursement of Mammography Screening for North Carolina Women 50-65 years of Age, Final Report to the N.C. Division of Health Services, Adult Health Services Section. Sub-contract for NCI Grant "Data Based Interventions for Cancer Control, 1989.

Simpson, K. and A. Fontain. Impact of Management Training for In-Charge Nurses on Rural Clinics in Kenya, Final Evaluation Report. INTRAH and USAID, 1988.

Proceedings

Voit EO, Schwacke LH, **Simpson KN**. Application of S-distributions to resource use and cost data in clinical and economic studies. Proceedings of the 2000 Joint Statistical Meeting. Indianapolis, August 13-17, 2000.

Simpson KN. Modeling in Cancer. Invited paper. The First European Conference on the Economics of Cancer. Brussels November 19-21, 1997. EORTC: European Organization for Research and Treatment of Cancer, Brussels, Belgium, 1997.

McLaughlin CP, **Simpson KN**, Johnson SP. A methodology for studying learning rates by organizational form in U.S. health care services: The example of premature labor. Proceedings of the European Operations Management Association, London Business School, 1997.

Simpson, K.N. The use of cost effectiveness analysis to inform investment decisions on research on the artificial heart and other evolving technologies. National Heart, Lung and Blood Institute. Proceedings from Expert Workshop. Bethesda M.D. January 23-24, 1993.

Simpson, K.N. Issues in decision modeling for early stage prostate cancer. Symposium on Early Prostate Cancer Treatment. American Urological Association, American Cancer Society in cooperation with the National Cancer Institute. Crystal City V.A. December 3-5 1993.

Simpson, K.N., C. King, S.R. Lynch, A. Rentz and C. Stevens. Cost of ultrasound screening in low-risk pregnancies. Proceedings. Symposium on the results of the RADIUS trial. National Institute of Child Health and Development 1993.

Simpson KN and DesHarnais SI. Criteria for selecting an approach to medical service area definition. Proceedings. 1991 Public Health Conference on Records and Statistics. National Center for Health Statistics. Hyattsville MD 20782.

Pathman, D.E., T.R. Konrad, and **K.N. Simpson**, "Utilization Review, Clinical Protocols, and Physician Satisfaction." Proceedings of the Health Services Research Fellowship Symposium. Dept. Of Family Medicine and The Health Services Research Center, University of North Carolina at Chapel Hill 1990.

RESEARCH

Current Research

Simpson (PI), Abbott GmbH & Co, Ludwigshafen, Germany 06/01/08 - 03/31/09
Model to predict cost and consequences of 2nd line antiretroviral AIDS therapy in Africa based on the DART study. Develop and Excel model of AIDS under competing mortality and morbidity of malaria and tuberculosis to estimate budget impact, disability-adjusted survival, number of orphans, number of children not in school, rural farm production hours lost, and medical and funeral cost to urban employers for Uganda and one other TBD country in Africa.

Simpson (PI), Abbott Laboratories, West Chicago Ill. 04/01/08 - 03/31/09
Cost effectiveness analysis based on the CASTLE study. Using the AIDS Markov and Discrete Event Simulation models to estimate costs, consequences, and budget impacts for antiretroviral-naïve patients in the US.

Simpson (PI), MUSC 04/15/07 – 04/14/08
CTSA Pilot Study to develop a discrete event model to estimate impacts of changes in stroke treatments in SC.
This study uses ARENA discrete event modeling to estimate changes in outcomes and costs for SC if tPA use was increased through a TeleStroke Program, ER stroke team implementation, and other interventions to decrease the morbidity and cost resulting from acute ischemic stroke. \$38,000

Baliga (PI) 07/01/2007-06/30/12
A Program to Increase Living Donations in African Americans
The goal of the application is to conduct a study to test the hypothesis that live kidney donation in African Americans will increase with: The utilization of educators who are professionally trained to work with African-American families, early identification and education of African-American donors in potentially high-yield settings, and navigation of the potential donors through the complex evaluation process by these educators.
Simpson Investigator 10% effort.

Simpson (PI), Neuronetics 01/08/06 – 01/07/08
Cost effectiveness of trans-cranial magnetic stimulation in severe depression.
An economic analysis of data from three clinical trials for depression for the purpose of reimbursement approval by funding agencies.

Nahas Z (PI), Cyberonics 04/08/07 – 03/30/08
To design a synthetic placebo control group from archival data to compare outcomes from vagus nerve stimulation treatments for severe depression.
Role: Co-PI 10% effort

Palesh Y (PI) 09/15/05 – 05/31/10
NIH/National Institute of Neurological Disorders and Stroke
The ALIAS/IMS3 Study. This is a pilot study and large trial to assess outcomes for stroke therapy.
Simpson Role: Co-investigator 5% effort Yr 3 budget \$113,482

Morrisette D. (PI) 08/01/06- 06/30/08
Clinical trial of elastic and inelastic lumbar-sacral support
Simpson Co-Investigator

Previous Funded Research

Simpson (PI), Exponent 07/01/06-07/30/07
Supitrol Clinical Trial of Obesity Interventions
Outcomes trial testing compound to prevent patient drop-out from weight loss regimens.

Simpson (PI), Abbot Labs II Amendment 04/08/06 – 04/14/08
Discrete Event Simulation Model of Kaletra and Atazanavir
The purpose of the study is to compare a previously developed AIDS model to a new discrete event model for estimating the long-term outcomes of competing highly active antiretroviral therapies (HAART).

RO1 DK062596 Baliga (PI). 09/15/02 – 06/30/07
NIH/National Institute of Diabetes, Digestive and Kidney Disease
A Program to Increase Living Donations in African Americans

The major goals of the project are to (a) assess specific barriers to live organ donations in African-American kidney transplant patients and their families, and (b) implement an educational intervention program to address these concerns and to eventually improve live organ donation rates among this population.

Role: Co-Investigator 5% Effort (MUSC Project #84144) Direct costs: \$150,000

Corporate Contract Simpson (PI). Boehringer Ingelheim Pharmaceuticals, Inc. 06/01/02 - 07/30/06

Economic and Quality of Life Component for the Phase III Clinical Trials of Tipranavir

The goal of the project is to design economic and quality of life studies to complement Phase III clinical trial data collection in multinational studies, and to perform the economic analysis required for approval and pricing. Role: Principal Investigator

Principal Investigator (Abbott Labs Project #84528) 01/01/2006 – 04/14/2007

Discrete Event vs. Markov Modeling Comparing Kaletra and Atzanavir in HIV-disease.

The major goal of the project is to compare the performance of two types of mathematical models to assess differences in patient outcomes on combination regimens containing Kaletra vs. Atzanavir. \$121,000

RO1 MH066004. Santos (PI) 9/18/2002-7/31/2007

Schizophrenia Liability Genes Among African Americans. Dr. Simpson is an investigator in charge of the data collection and quality measures. National Institute of Mental Health.

Role: Co-Investigator 5% effort.

U01 NS054630 Palesh (PI). 9/15/2005-5/31/2010

NIH/National Institute of Neurological Disorders and Stroke. The ALIAS/IMS3 Study

Pilot study and large trial to assess outcomes for stroke therapy.

Role: Co-investigator 5% Effort (MUSC Project # 05070890) Direct costs: \$791,155

Investigator. EXPORT Center on Metabolic Syndrome: Investigator Development Core. Research mentor for minority faculty. . NIH National Center for Minority Health Disparities 1P60 MD000267. 9/30/00- 8/31/07

Investigator. Southeastern Node, National Institute on Drug Abuse's Clinical Trial Network (CTN). As the economist for the node, she will provide methodological support for the design of economic and health services research studies and consultation for analysis of resource use and cost data. 10/1/00-9/30/05

Principal Investigator. Effects of adherence to ARV regimens on outcomes and cost in HIV-disease. GlaxoSmith-Klein. 9/16/04-7/31/05.

Principal Investigator. Two economic and quality of life "piggy-back" trials to complement the multinational Phase III clinical trials of Tipranavir salvage therapy. Boehringer Ingelheim 08/15/02-08/14/05.

Project Leader. Economic Access to Antiretroviral Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina. Study to identify black Medicaid patients with HIV-disease who appear to receive sub-optimal ARV therapy, and providers who have few HIV patients, and design a process to improve ARV care in S.C. Program Grant for Understanding and Eliminating Health Disparities from Agency for Healthcare Research and Quality HS-00-003. Total Project Direct Costs: \$534,900. 10/01/2000 to 10/31/2005

Co-Project Leader: Improving Care for High Risk Minority Patients with Chronic Illnesses by Using Pharmacist Consultations to Follow up on Missed Prescription Refills. Study will examine the impact of using a commercial pharmacy order-entry software program to identify patients at high risk for missed prescriptions, and the use of pharmacist counseling to improve medication adherence. The interventions will be aimed at for patients with hypertension, heart failure, diabetes, and/or depression. Program Grant for Understanding and Eliminating Health Disparities from the Agency for Healthcare Research and Quality HS-00-003. Total Project Direct Cost: \$375,682. 10/01/2000- 10/31/2005

Principal Investigator. Economic evaluation of Kaletra and Atzanavir. Abbott Laboratories. 7/1/2003- 12/31/2004.

Co-Principal Investigator: Cost effectiveness of cervicography vs. colposcopy in high-risk women in SC public health clinics. Model the cost effectiveness of using screening cervicography in women with positive PAP smears. Department of Defense/Hollings Cancer Center. Total Direct Costs \$93,702. 06/01/01-05/30/02.

Principal Investigator: S-Distribution Pilot Study. Develop and program a maximum likelihood estimator capable of testing the differences between two S-distributions, and use this estimator to reanalyze outcome and cost data from clinical trials to test the ability of this approach to improve study power to detect important differences in outcomes for measures with severely skewed and/or bimodal distributions. Funding for programming support. University Research Committee, MUSC. Total Direct Costs: \$18,000. 5/01/2000-4/31/2001.

Principal Investigator: Pilot Study for Standardized Indicators of Cancer Control Impact. This study will develop and pilot test a set of standardized indicators for four major cancers (breast, cervical, colon, and prostate) from health billing and cancer registry data. The indicators will include measures relevant to screening, treatment, and follow-up, and will be designed for use in monitoring and evaluating cancer early detection at the state level. Department of Defense/Hollings Cancer Center. Total Direct Costs: \$80,000. 06/01/2000-5/30/2001.

Core Investigator. : Clinical Trials Network: South-Eastern Node. To develop an infrastructure for drug abuse treatment research through a partnership of the MUSC and a network of community treatment programs (CTPs) in the South-Eastern United States in order to (1)conduct clinical trials in a number of areas, including pharmacologic, behavioral, combined pharmacologic/behavioral practice, health services and dissemination research and (2) work collaborative with other Nodes in the NIDA Clinical Trials Network. B. In collaboration with the Steering Committee of the Clinical Trials Network and NIDA, to develop and organizing framework for the Network, including policies on protocol development and review, publications and dissemination, quality control and data management, selection of assessment batteries and outcome measures, treatment development and therapist training, and clinical care. Dr. Simpson is part of the Health Services Research Core, and will provide support for the HSR design and analysis components, with special emphasis on outcomes measurement and economic studies. National Institute on Drug Abuse. Total Direct Cost: \$12.2 million. Start Date: 9/30/2000 End Date: 8/31/2005

Investigator. Veterans Evidence-Based Research Dissemination Implementation Center (VERDICT). Provide consultation on the design of health economics and health services research studies. VA Centers of Excellence Program. San Antonio TX and Charleston SC. 10/1/99-9/30/2003

Principal Investigator. Pharmaco-economics of ABT 378/r for US Patients, and Adaptation of the US model to Brazil, Canada, France, Germany, Italy, the Netherlands, and Spain. Develop an estimating model that uses Abbott clinical trial data from FDA submission, UK, Dutch, and US archival data from an AIDS patient repository at Oxford University (U.K.) and archival/or prospectively collected economic data from each country to estimate differences in survival and cost of care for patients treated with ABT 378 vs currently available drugs. Abbott Laboratories, Therapeutics Division. Total direct cost \$168,000. 11/1/99-12/31/2000.

Principal Investigator. Economics of Pletal vs. Trental for Intermittent Claudication. Modeled improvement in outcomes and costs for patients with intermittent claudication: a comparison of Trental and Pletal based on updating a published model, meta analysis of clinical trial results and archival data analysis. Pharmacia & Upjohn.

Project Director. Cost Functions for Billing Data. Development of methods to use archival data from medical care billing and other repository systems to "fingerprint" institutions' practice patterns and resource use to allow pattern recognition of adherence to guideline for clinical information systems. Chiron Informatics (**US patent received**).

Project Director. Cancer Disease Models. Development of a system of models (based on archival data) to estimate disease incidence, prevalence and lifetime cost of care for patients with lung- bladder- hepatic-cancer, hemophilia, diabetes, osteoporosis, HIV-disease, heart disease and other complex chronic conditions. These models are used to assess research investment opportunities for developments of biotechnology product lines. Nucleic Acid Diagnostics and Therapeutics Divisions, Chiron.

Principal Investigator. Cost of Illness for Patients with AIDS and Other Severe Chronic Conditions. Glaxo Wellcome, Research Triangle Park, NC. Using archival data from multiple sources to estimate disease and cost burden of complex chronic conditions.

Principal Investigator: Pediatric Allergy Learning Study: Quality of life and Economic Component (Protocol 96-219). ACER- Schering Plough.

Investigator. Economic Model for Parkinson's Disease. Research Triangle Institute, NC.

Principal Investigator. Methodological Support for the Development of Guidelines for Management of Autonomic Dysreflexia. Paralyzed Veterans of America, Washington DC.

Principal Investigator. Multinational Trial of Protease Inhibitor AB247 in End-stage AIDS- Economic Component. Abbott Laboratories, Chicago IL.

Principal Investigator. Outcomes, Cost of Illness and Reimbursement Patterns for Septic Shock Patients. Bayer Corporation, West Haven CT.

Principal Investigator. Model Estimates of Costs and Consequences of Combination Therapies with Antiviral Drugs. Roche Laboratories, Nutley NJ.

Principal Investigator. Methodological Support to the Expert Panel on Guidelines for Management of Deep Vein Thrombosis in Paralyzed Individuals. Paralyzed Veterans of America, Washington DC.

Principal Investigator. Model Estimates of Combination Therapy with Antiviral Drugs in Five European Countries, Australia and Canada. Hoffman-La Roche, Basel Switzerland.

Principal Investigator. Case-study Series of Practice Variations and Cost of Therapy for HIV-Infected Patients with Idiopathic Thrombocytopenia (ITP). UNIVAX Inc, Rockville MD.

Principal Investigator. Development of a Pharmaco-Economic Decision Support Model for AIDS Program Management. Roche Laboratories, Nutley NJ.

Principal Investigator. Pilot Project to Assess the Cost-Effectiveness of Drug Utilization Evaluation Programs in Veterans Administration Hospitals, Quality Management Institute, Durham, NC.

Principal Investigator. Cost Effectiveness of Rifabutin Prophylaxis in AIDS patients in the United Kingdom. Battelle Medical Technology and Policy Research Center, Washington, DC, 1993-1994.

Principal Investigator (Economic Component). Cost Utility of new antiviral drugs in AIDS patients in the United States. Battelle MEDTAP, Washington DC

Principal Investigator. Economic analysis to support Consensus Panels on 1) Excessive Use of Ultrasound Technology in Normal Deliveries; and 2) Use of Antenatal Steroids in premature deliveries. National Institute of Child Health and Human Development. N.I.H. Bethesda, M.D.

Principal Investigator (Economic component). "The effect of tiludronate for the treatment of vertebral fractures in post-menopausal women. Battelle MEDTAP, Washington DC, 1993-1997.

Co-principal Investigator. The effect of rural hospital closure on cost and outcomes for Medicare beneficiaries. Agency for Health Care Policy and Research. Grant # 1R01-HS07029-01A1. January 1993-June 1995.

Principal Investigator. "A cost effectiveness study of antiviral treatment with zalcitabine in combination with zidovudine for AIDS patients with CD4 counts < 300 per mm³: development of a base model and its adaptation to Switzerland, Germany, France, United Kingdom and Italy." Battelle Medical Technology and Policy Research Center. Washington DC. 1992-1993.

Principal Investigator. "Cost utility analysis of rifabutin for the prevention of Mycobacterium Avium Complex (MAC) disease in AIDS patients." Battelle Medical Technology and Policy Research Center. Washington DC., 1992-1993.

Principal Investigator. "Development of a strategic investment model to forecast the cost effectiveness of new pharmaceutical compounds prior to the institution of clinical trials."Battelle Medical Technology and Policy Research Center, Washington DC., January-September 1992.

Economist. "The cost of tuberculosis in the United States in 1992. Centers for Disease Control, Atlanta GA." Battelle Medical Technology and Policy Research Center. Washington DC.

Principal Investigator. The development of a conceptual model to estimate the interaction between the technical and clinical production functions of the use of bed-side blood analysers in cardiac intensive care patients. Battelle Medical Technology and Policy Research Center. Washington DC.

Principal Investigator. "Development of a Model to Predict the Impact of Investments in Childhood Vaccination Research on Medical Costs and Outcomes." Contract # 263-MD-142293, NIAID, National Institutes of Health. 1991-92. Second award given 1992/93.

Co-Principal Investigator. "Effects of Hospital Closures on Medicare Multiple ADM Patients." National Institute of Mental Health. RO 1 Grant. 1991-94.

Awardee. Faculty Fellowship in Health Care Finance. The Robert Wood Johnson Foundation, 1991-1994 (one of six awards given).

Principal Investigator. "Diffusion and Adoption of Total Quality Management in Hospitals. 1991 Health Care Management Research and Teaching Case Study Development Award, American College of Healthcare Executives (one annual recipient).

Health Economist. Economic Aspects of the Measurement of Effectiveness in the Evaluation of Community Programs for Clinical Research on AIDS." Contract. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Investigator. "Evaluation Design for Community Programs for Clinical Research in AIDS." Contract. Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH.

Principal Investigator. "Community Health Center Teaching Case Development Project." Contract. National Primary Care Institute, Washington, DC.

Principal Investigator. "Management Staff Training Contract," North Carolina Division of Mental Health, Mental Retardation and Substance Abuse.

Project Director. "Pilot Program on Strategic Fiscal and Human Resources Management." Contract. National Primary Care Institute, National Association of Community Health Centers.

Principal Investigator. "A Case Study of Rationing in a National Health System: Denmark." Grant. The University of North Carolina Foundation.

Principal Investigator. "Re-evaluation of the Florida REACH Program". Grant. The Robert Wood Johnson Foundation.

Principal Investigator. "Data Based Interventions for Cancer Control." National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. Mapping of questions for using 20 archival data sources in North Carolina to inform State level cancer control planning and monitoring efforts. 1988

Consultant/Research Scientist. "Small Area Analysis Medical Assessment Pilot Project". To perform the analysis and interpretation of results of Medicare billing data for North Carolina to assess small area variations in hospital admission rates, outcomes and costs for inpatient care. Sub-contract with Medical Review of North Carolina (PRO) on grant from Health Care Financing Administration, Health Standards and Quality Bureau Contract #500-88-004.

Technical Consultant. "Final Evaluation of Management Training Program for In-Charge Community Nurses in Kenya." Technical Leader of Ministry of Health and INTRAH Evaluation Team. US-AID.

Project Director. "Data Based Interventions for Cancer Control." National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. Mapping of questions for using 20 archival data sources in North Carolina to inform State level cancer control planning and monitoring efforts. 1988

PUBLISHED ABSTRACTS

Simpson KN. Approaches to Maximize Study Power for Economic Endpoints in Fixed Sample Size Clinical Studies. International Society for Clinical Biostatistics. Abstract #211. Annual Meeting, August 22, 2008, Copenhagen, Denmark.

Basco WT Jr., Ebeling M, Hulsey TC, Simpson K. Estimating Rates of Look-Alike, Sound-Alike Substitutions in Pediatric Prescriptions Using Pharmacy Data. Presented at the Child Health Special Interest Group session of Academy Health. Annual Research Meeting, Washington, DC, June 7, 2008.

Simpson KN, Nahas Z, Leuchter AF, Siegel A, Greenwald S. Cost Utility of EEG Biomarkers for Personalized Treatment of Major Depression. International Society of Pharmacoeconomics and Outcomes Research. Annual Meeting, Toronto, Canada, May 5, 2008.

KN Simpson, A Strasburger III, W Jones, R Rajagopalan, B Dietz. Comparison of Markov and Discrete Event Simulation for HIV-Disease. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago September 17, 2007.

Margaret C. Garin, BA; Elinor C.G. Chumney, PhD, MSc; Kit N. Simpson, DrPH; Kristin B. Highland, MD, MSCR Cost-utility of Treatments for Pulmonary Arterial Hypertension. Chest 2007, Chicago October 25, 2007.

Risebrough N, Simpson K, Mittmann N. Economic Evaluation of Tipranavir in the Treatment of Human Immunodeficiency Virus. ISPOR Toronto, May 15, 2008.

Simpson KN, Nahas Z, Leuchter AF, Siegel A, Greenwald S Cost Utility of EEG Biomarkers for Personalized Treatment of Major Depression. ISPOR Toronto, May 15, 2008.

Simpson KN, Nahas Z, Leuchter AF, Siegel A, Greenwald S. Cost Effectiveness of Biomarkers for Rapid Identification of Response to Escitalopram in Major Depression. NCDEU. May 20, 2008.

Nahas Z, Simpson AC, Simpson KN. Modeling antidepressant properties of vagus nerve stimulation (VNS therapy) in the context of a 12 months long placebo controlled study. Society of Biological Psychiatry. 63rd Annual Meeting, Washington, DC, May 1-3.

Nahas Ziad ; Borckardt Jeff ; **Simpson Kit**, Simpson Annie; Forster Lauren; Mu Qiwen ; Bohning Daryl E. ; George Mark S. Vagus Nerve Stimulation In Treatment-resistant Depression. Canadian Psychiatric Association Meeting, Montreal, November 15 -18, 2007.

Brian P. McKinzie, PharmD, Cathy L. Worrall, PharmD, BCPS, BCNSP, FAPhA, **Kit N. Simpson**, DrPH, E. Douglas Norcross, MD, Stuart Leon, MD. Impact of Elevated Percent Carbohydrate-Deficient Transferrin at Hospital Admission on Outcomes in Trauma Patients. AACP Spring Practice and Research Forum, Memphis, TN, April 21, 2007.

Goodnight W, **Simpson K**, Soper D. Cost-effectiveness of antenatal maternal CMV serological screening for reduction of congenital CMV sequelae. OB/GYN Infectious Disease Society. April 2007.

Marculesque C, **Simpson KN**. Total Joint Replacement Volume and In-Hospital Mortality During Treatment of Prosthetic Joint Infections (PJIs). Podium presentation at the 16th Annual Open Scientific Meeting of the Musculoskeletal Infection Society, August 11-12, 2006, at The Resort at Squaw Creek, Lake Tahoe, CA.

Simpson KN, Jones W, Rajagopalan R, Dietz B. Cost Effectiveness of Lopinavir/ritonavir compared to Atazanavir + Ritonavir Tablets in Antiretroviral (ARV) Experienced Patients in the UK, Spain, Italy, and France Based on Efficacy Results from BMS AI424-045. Eighth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006.

Simpson KN, Rajagopalan R, Dietz B. Predicted Future Effects of Level of Viral Load (VL) Suppression by the 36th Week. Eighth International Congress on Drug Therapy in HIV Infection Glasgow November 2006

Kelby Hutcheson, **Kit Simpson**. Effects of Preoperative Chronic Opioid Use on Length of Stay and Cost for Patients Undergoing Routine Surgical Procedures: identification of a novel risk factor.

Koya DL, Castell DO, Vela M, **Simpson K**. Cost-effectiveness of Impedance pH testing in persistent reflux-related cough despite acid suppressive therapy. . Digestive Diseases Week (DDW), Annual meeting of AGA, May 19-24, 2007 in Washington, D.C.. Gastroenterology 2007.

Garrow D, **Simpson K**, Romagnuolo J. Markov economic model for surgery in the morbidly obese. Digestive Diseases Week (DDW), Annual meeting of AGA, LA, California, 2006 (oral presentation). Gastroenterology 2006; 130: A55 (Abstract).

Simpson KN, Chumney ECG, Hicks CB, Finnern H. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the USA. ISPOR Philadelphia May 20-24, 2006

Kelly Goodson, PharmD; Cathy Worrall, PharmD, BCPS, BCNSP, FAPhA; English Barbour, RD, CNSD; **Kit Simpson**, DrPH; Mark DeLegge, MD. Impact of Permissive Underfeeding on Outcomes in Surgical-Trauma ICU Patient. Poster Nutrition Week, Aspen CO, Jan 28, 2007.

Simpson KN, MacKinnon G. Economic and Clinical Impact of Using A Protease Inhibitor Regimen Containing Atazanavir + Ritonavir vs. Lopinavir/ritonavir in Antiretroviral (ARV) Experienced Patients: Modeling the Lifetime Impacts of the 48 Week Results from BMS AI424-045. The XVI International AIDS Conference, Toronto 13-18 August 2006.

Cathy Worrall, English Barbour, Brent Anderegg, **Kit Simpson**, Mark DeLegge. Correlation of Standard Equations to Estimate Caloric Requirements versus Measured Resting Energy Expenditure in Obese Hospitalized Patients. ASPEN Meeting, Dallas, Tx, February 2007.

Spencer AP, **Simpson KN**. Health Benefit and Economic Impact of Hemofiltration in High-Risk Patients Undergoing Coronary Angiography. Society for Cardiovascular Angiography and Interventions. (SCAI) 29th Annual Scientific Sessions in Chicago from May 10-13, 2006.

P Baliga, MD, S Lunsford, MS, G Smalls, MBA, G Gilbert, MSPH, J Milton, BSN, MBA, L Hildebrand, BSN, L Shilling, PhD, M Martin, PhD, M Norman, PhD, **KN Simpson**, and K Chavin, MD, PhD. Asking For A Live Donor Kidney: Recipient Concerns. UNOS Conference, April 2005, Memphis, TN.

KN Simpson, MP Luo, EC Chumney, J Macyck, M King, S Brun, T Ashraf. Cost Effectiveness of Lopinavir/r vs. Atazanavir in Treating Antiretroviral-naïve Patients: Modeling the Combined Effects of HIV and Heart Disease. 7th International HIV Congress on Drug Therapy in HIV Infection. November 17, 2004, Glasgow, UK.

Gomez J, **Simpson KN**, Cantey JR. Epidemiology of Prosthetic Joint Infections (PJI) in SC. 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), October 1, 2004, Boston, MA.

Cook JA, Grey D.D., Cohen M. H., Burke J., **Simpson K**. Impact of HAART Use on Medical Treatment Costs in a U.S. Multisite Cohort of HIV+ Women. International AIDS Conference, Bangkok, Thailand, July 7-16, 2004.

Simpson KN, Sarang R., Chumney E., Mazyck-Brown, J. Disparity in Use of Highly Active Anti-Retroviral Therapy (HAART) for Medicaid Patients with HIV/AIDS in South Carolina. 2004 Academy of Health Meeting, San Diego, CA, June 6 - 8, 2004.

Simpson KN, Bradford D, DesHarnais S, Hunz M, Lunsford S, Zapka J. Race and Age-related Differences in Hospice Care at the End of Life for Cancer and Heart Failure Patients. 2004 Academy of Health Meeting, San Diego, CA, June 6 - 8, 2004.

Gary, HG, **Simpson, KN**. White and Black Disparities in the Burden of Disease Related to Ageing. MUSC Conference on Ageing, March 2004, Charleston, SC. 2004 Academy of Health Meeting, San Diego, CA, June 6 - 8, 2004.

Chumney, E, **Simpson KN**, Cheng K. Expected Quality of Life and Cost Implications of R-Shop and Radioimmunotherapy Regimens for Indolent Non-Hodgkin's Lymphoma. AphA2004 Annual Meeting and Exposition, March 26-30, 2004, Seattle, Washington.

Simpson KN, Berzon R. The health and economic costs of resistance to antiretroviral therapy. Poster presentation # 818. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris France 13-16 July, 2003.

Gladney D, **Simpson KN**. Hypertension: What Factors Make African American at Higher Risk for Developing Cardiovascular Disease. MUSC Student Research Day October 2003.

Grate E., **Simpson KN**, Santos A. The Effects of Highly Active Antiretroviral Therapy on Triglyceride and Cholesterol Levels in Patients with HIV/AIDS. Annual Conference 2003 of the American Chemical Society, Anaheim, CA
Bond S., **Simpson K.**, Soper D. Patterns of Participation in Care Among Low-income Rural Women with Abnormal Papanicolaou Results. The American College of Nurse Midwives Annual Meeting, Palm Desert, CA June 4, 2003.

AT Siachos, AB Van Bakel, AJ Crumbley, DS Feldman, J Ikonimidis, W. Uber, **K. Simpson**, NL Pereira, *Race and Silent Cerebral Infarction in Patients with Dilated Cardiomyopathy Being Evaluated for Heart Transplantation*. Heart Failure Society of America 6th Annual Scientific Meeting, 2002.

Elinor C.G. Chumney, M.Sc. and **Kit N. Simpson**, Dr. P.H., *The Potential Effect of Data Sources and Analytic Approaches to the External Validity of Economic Studies: SC Medicaid vs. HCSUS Data*. International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting May 20, 2002.

PG McBurney, **KN Simpson**, and PM Darden. *Expected Savings From Decreasing Emergency department Visits through Greater Continuity in a Medical Home*. Presented; Southern Societies Meeting, New Orleans, February 2002. *Journal of Investigative Medicine*, January 2002; 50(1): 106A (558).

PG McBurney, **KN Simpson**, and PM Darden. Potential Cost Savings of Decreased Emergency Department Visits Resulting from Increased Continuity in a Medical Home. 2002 Pediatric Academic Societies' Meeting, Baltimore May 2002.

Kit N. Simpson, Dr.PH, Holly Yu, MS, Rajesh Sarang, MD, MPH *Racial and Gender Disparities in the Use of Antiretroviral Medication for AIDS/HIV among Medicaid beneficiaries in South Carolina*. Academy for Health Services Research and Health Policy Annual Research Meeting, June 23-25, 2002, Washington, D.C.

Deborah S. Carson, PharmD, Wenle Zhao, PhD, Pamela Mazyck, PharmD, Russell A. Goodman, B.S., **Kit N. Simpson, Dr.PH**. A Pharmacy Informatics System For Maximizing Refill Compliance In Chronic Disease Management. Academy for Health Services Research and Health Policy Annual Research Meeting, June 23-25, 2002, Washington, D.C.

Simpson KN, Voit EO, Goodman R, Ashraf T, Sun E. Development of a Markov Model to Forecast HAART Regimens' Clinical Outcomes and Resource Utilization. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto Canada, September 17-20, 2000.

Simpson KN, Marshall DA, Earle CC, Chu C. Economic model of screening for lung cancer. Second European Conference on the Economics of Cancer. Brussels, September 3-5, 2000.

Simpson KN, EO Voit, R Goodman. Data requirements of second-generation economic models in HIV/AIDS. ISPOR 5th Annual Meeting. Washington, DC. May 22, 2000.

Simpson K.N., E.O.Voit, R. Goodman, T. Ashraf, J. Hutton, E. Sun. A Second Generation Model for Exploring Impacts of Sequential Regimens of HAART, Adherence Differences, Resistance Patterns, ART Change Criteria, and Drug Side Effects on Survival, Quality of Life, and Lifetime Cost of Illness for PVAs in the US. XIII International Conference on AIDS, Durban South Africa. July 8-9, 2000.

Voit EO, RA Goodman, **KN Simpson**. Analysis of health and economic outcomes in HIV/AIDS models, using S-distributions. International Biometrics Society Meeting. San Francisco. July 2-7, 2000.

Voit EO, Schwacke LH, **Simpson KN**. Application of S-distributions to resource use and cost data in clinical economic studies. 2000 Joint Statistical Meeting. Indianapolis, August 13-17, 2000.

Simpson KN, Marshall DA, Earle CC, Chu C. Economic decision analysis for lung cancer screening. International Society for Technology Assessment in Health Care, Hague, N.L. June 18-21, 2000.

Marshall DA, **Simpson KN**, Earle CC, Chu C. Potential Cost-effectiveness of One-Time Screening for Lung Cancer (LC) in a High Risk Cohort. 9th World Conference on Lung Cancer. International Association for the Study of Lung Cancer. Tokyo, Japan, September 11-15, 2000.

Simpson, KN. Budget impacts of the integration of genotypic antiretroviral resistance testing into HIV treatment guidelines. 7th Conference of Retroviruses and Opportunistic Infections. San Francisco, February 2, 2000.

Marshall DA, **Simpson KN**. Assessment of methods for analysis of guideline data in chronic diseases. Society for Medical Decision Making. Reno NV, October 3-6, 1999.

Chong BS, Warren SK, Bonapace CR, **Simpson KN**. A pilot study of impact of guideline implementation on the use of benzodiazepines in patients with discharge diagnosis of alcohol withdrawal or delirium tremens. 1999 Chicago.

Simpson KN. Methodological issues in study design: New research paradigms from other fields. Consensus Development Conference on Treatment of Persons with Traumatic Brain Injury, National Institutes of Health, October 26-28, 1998.

Simpson KN. Clinical economics in HIV+: Saving money or saving lives? British HIV+ Association, Royal College of Physicians, London, U.K. September 26, 1998.

Simpson KN. Health economics in R&D decision making for biotechnologies. Drug Information Association, Conference on The Role of Pharmacoeconomics in Pharmaceutical R&D Decision Making. London, UK October 13-15.

Marshall DA, **KN Simpson**, J McHutchinson, M Martinot, J-M Pawlotsky, P Marcellin, R Perrillo. Comparison of therapeutic strategies for treatment of hepatitis C (HCV) patients with Alpha Interferon. Abstract 16849. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego CA, October 10, 1998.

Marshall DA, **KN Simpson**, J McHutchinson, M Martinot, J-M Pawlotsky, P Marcellin, R Perrillo. Economic analysis of viral load testing at 3 months to guide treatment decisions for patients with chronic hepatitis C. American Association for the Study of Liver Disease. 49th Annual Meeting. Chicago IL, Nov. 10, 1998.

Simpson KN, Marshall D, Thompson P. Measurement of Adherence to Clinical Protocol and Patient Outcomes: Examples from HIV+ Disease. 12th World AIDS Conference. Geneva, Switzerland. July 2, 1998.

Marshall DA, **Simpson KN**, Thompson P. Measurement of adherence to clinical guidelines and patient outcomes: Example of guidelines in HIV+ disease. Analysis International Society for Technology Assessment in Health Care, Ottawa, Canada, June 7-10, 1998.

LaVallee R, **Simpson KN**, Thompson P. Breast Cancer, Bone Metastasis and Episodes of Care: A Basis for Cost Effectiveness Analysis. International Society for Technology Assessment in Health Care, Ottawa, Canada, June 7-10, 1998.

Richter A, **Simpson KN**, Mauskopf J. Prediction of costs and outcomes for HIV patients monitored with viral load versus CD4 cell counts. 5th Conference on Retroviruses and Opportunistic Infections. Chicago IL, February 4, 1998.

Simpson KN, Marshall D. Estimation of standard cost values from published studies: Example from AIDS. International Society for Technology Assessment in Health Care, Barcelona, Spain May 1997.

McLaughlin CP, **Simpson KN**, Johnson SP. A methodology for studying learning rates by organizational forms in U.S. health care services: The example of premature labor. European Operations Management Association (EurOMA) Barcelona, Spain, June 15-18, 1997.

Biddle AK, **Simpson KN**, Fiscus SA. Current Practice vs. Mandatory Prenatal HIV Testing: Costs and Outcomes in North Carolina 1993-1996. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC Jan 1997.

Simpson KN, LaVallee RL. Combination therapy in eight developed countries: Events and costs of therapy with saquinavir, zalcitabine and zidovudine therapy in Australia, Canada, Germany, Italy, Spain, Switzerland, UK, and USA. 3rd International Congress on Drug Therapy in HIV Infection. Birmingham, UK. November 5, 1996.

Simpson KN, Revicki D, Nabulsi A, Sarocco P. Outcomes and costs for patients treated with combination therapy including a protease inhibitor: A comparison of modeled estimates with prospectively collected data on events and resource use in a multinational study of ritonavir. Xth International Conference on AIDS. Vancouver Canada, July 7-12, 1996.

Portela M, **Simpson K**, Guess H, Sen PK. A Markov model for the estimation of Outcomes and costs for AIDS populations. International Society for Technology Assessment in Health Care. San Francisco CA June 24, 1996.

Russo MW, Helm JF, **Simpson KN**, Ransohoff DF, Wurzelman JI, Sandler RS. Weighing the benefits and risks of low-dose aspirin in primary prevention of colorectal cancer. Annual Meetings of American Gastroenterology Association and American Association of the Study of Liver Diseases. May 19, 1996.

Simpson KN. Expected Health and Economic Consequences of Mono-, Double and Triple Antiviral Therapy. 3rd Conf. on Retroviruses. Infectious Disease Society of America. Washington D.C. January 30, 1996.

Mauskopf J, **Simpson K**. The Costs and Benefits of Alternative Drug Treatment Regimens for HIV Patients. 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Disease Society of America. Washington D.C. January 30, 1996.

Portela MC, **Simpson KN**, Guess HA, Sen PK. Clinical Predictors of Hospital Resource use for Patients with AIDS. Medical Decisionmaking 15:4 423.

Portela MC, **Simpson KN**. A Markov Model for the Estimation of Costs in the Treatment of AIDS Patients. 2nd Surrogate Markers Conference. McLean VA, October 1995.

Simpson KN, LaVallee RL, Revicki DA. Cost Effectiveness and Survival of AIDS patients in Rifabutin Prophylaxis for MAC: estimated for the United Kingdom. International AIDS Conference. Copenhagen, October 1995.

Simpson KN. Design and Measurement Issues in Economic Studies of Therapy for Chronically Ill Populations: Examples from HIV-Disease. International Society for Technology Assessment in Health Care. Stockholm June 1995.

Simpson KN, LaVallee RL, Revicki DA. Outcomes and costs of short- and longterm rifabutin prophylaxis for Mycobacterium avium (MAC) disease in AIDS patients in the United Kingdom. Second International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, Nov. 1994.

Simpson, KN and SI DesHarnais. Integrating Risk Adjustment and Cost Effectiveness Analysis into CQI Studies. International Society for Quality Assessment, Venice, Italy May 26, 1994.

Simpson, KN and SI DesHarnais. Assessing Cost Effectiveness, Investment Value and Budget Impact of Drug Utilization Evaluation Programs in Hospitals. International Society for Quality Assessment, Venice, Italy May 26, 1994.

DesHarnais, SI and **KN Simpson**. A Model for Assessing and Selecting Case Mix (Severity and Risk) Measures for Quality Evaluation Studies. International Society for Quality Assessment, Venice, Italy May 26, 1994.

Halpern, M, **KN Simpson**, C Palmer, R LaVallee, F Chesley and B Luce. Evaluating the Joint Clinical and Laboratory Consequences of a New Medical Technology: Assessing the Economic Impact of a Point-of-Care Blood Analyzer. Assoc. for Health Services Research, San Diego CA, June 13, 1994.

Simpson, KN, BR Luce, MT Halpern and F Chesley. The Marginal Cost Effectiveness of Using Three Laboratory Test Production Processes for the Management of Cardiac Surgery Patients in Intensive Care Units. International Society for Technology Assessment in Health Care, Baltimore, MD, June 21, 1994.

Halpern, MT, CS Palmer, **KN Simpson**, FD Chesley and BR Luce. Developing a Clinical Model Without an Underlying Clinical Condition. International Society for Technology Assessment in Health Care, Baltimore, MD, June 21, 1994.

Simpson KN. The Use of Cost Effectiveness Data for Informing Formulary Decisions for AIDS Therapy. Institute for AIDS Policy Makers. RWJ Medical School, Newark, NJ. Nov. 29, 1993.

Simpson KN Issues in Modeling Prostate Cancer Therapy and Outcomes. Symposium on Therapy for Early Prostate Cancer. American Urological Society, American Cancer Society and The National Cancer Institute. Crystal City, VA. Dec. 5 and 6, 1993.

Simpson KN The Use of Economic Analysis for Assessing the Value of Competing Programs. Quality Management Institute, Durham Veterans Administration Hospital. Jan. 3, 1994.

Simpson KN The Role of Cost Effectiveness Analysis in Research and Development of Evolving Technologies. Workshop on the Artificial Heart: Planning for Evolving Technologies. National Heart, Lung, and Blood Institute. Bethesda MD. Jan. 23-24, 1994.

Simpson KN Cost Effectiveness of Adding ddC to AZT for German AIDS Patients. Experten-Workshop: Therapie-Strategien Gegen HIV Status 1994 und Perspektiven [Consensus Conference on Antiviral Therapy]. Kronberg, Germany. April 22-23, 1994.

Simpson KN The Marginal Cost Effectiveness of Competing Therapies for AIDS. Policy Advisory Board for AIDS Drugs. Hoffman-LaRoche, Inc., Nutley NJ. May 5, 1994.

Simpson KN Comparing Vaccines and Vaccine Improvements. National Vaccines Advisory Committee, Future Vaccines Subcommittee. PHS, Rockville MD. June 3, 1994.

Simpson, K.N., R. LaVallee, D. Revicki. Cost-Effectiveness of Rifabutin Prophylaxis in Persons with AIDS. IXth International Conference on AIDS, Berlin, Germany June 7, 1993.

Simpson, K.N., E.H.Hatziandreu, F. Anderson, A. Shakespear, I. Oleksy, A. Goll. Effectiveness and Cost of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in Germany, France, Italy, United Kingdom and Switzerland. IXth International Conference on AIDS, Berlin, Germany June 7, 1993.

Hatziandreu, EH, **K.N. Simpson**, F. Anderson, A. Shakespear, I. Oleksy, A. Goll. Cost of Treatment for Opportunistic Disease Episodes for AIDS Patients in Germany, France, Italy, United Kingdom and Switzerland. IXth International Conference on AIDS, Berlin, Germany June 7, 1993.

Simpson, K.N. Do Randomized Clinical Trials Answer the Questions That Policy Makers Need Answered? Ninth Annual Meeting of ISTAC, Sorrento, Italy, May 23-26, 1993.

Simpson, Kit N., and Susan I. DesHarnais. The Integration of Outcomes Measurement and Cost Effectiveness Analysis Techniques into Total Quality Management Programs (Abstract). Ninth Annual Meeting of ISTAHC, Sorrento, Italy, May 23-26, 1993.

Simpson, K.S., F. Anderson, A. Shakespeare, I. Oleksy and E.J. Hatziandreu. A Conceptual Framework for Trans-national Modeling of Cost Effectiveness: An Example from AIDS Treatment in Europe (Abstract). Ninth Annual Meeting of ISTAC, Sorrento, Italy, May 23-26, 1993.

Simpson, K.S., F. Anderson, A. Shakespeare, I. Oleksy, E.J. Hatziandreu and A. Tosteson. Using Intermediate Outcome Measures from Very Early Phase 1/2 Clinical Trials to Model Cost Effectiveness: AZT plus ddC Antiviral Treatment in Switzerland. Ninth Annual Meeting of ISTAHC, Sorrento, Italy, May 23-26, 1993.

Simpson, Kit N., and Ruth E. Brown. Cost Effectiveness of Adding Prostate Specific Antigen (PSA) Test to Digital Rectal Examination (DRE) for Early Detection of Prostate Cancer. Eighty-Eighth Annual Meeting of the American Urological Association. San Antonio, TX May 19, 1993.

Simpson, Kit N., and Ruth E. Brown. Cost Effectiveness of Prostate Specific Antigen and Digital Rectal Examination in the Detection of Prostate Cancer. Paper presented at the Annual Meeting of the American Public Health Association, Washington, DC November 10, 1992.

McLaughlin, C, **Simpson, K,** Kaluzny, A. "Service Quality, then Productivity in Health Care: an Industry with High Activity and Perhaps Innovation." The Wharton Conferences on Service Management, Technology and Economics, Philadelphia PA, 1992.

Simpson KN Market Rationing or Needs-Based Rationing: Comparing Access and Biases for Denmark and the United States." APHA Annual Meeting, Atlanta GA, November 12, 1991.

Simpson KN Diffusion of Health Care Innovations Across National Borders: A Comparison of Medical Technology, Quality Management, and Financing Methods used in Iceland, Denmark and Holland." With Gudrun Hognadottir and Arnout Siegelar. APHA Annual Meeting, Atlanta GA, November 12, 1991.

Simpson, K.N. and S.I. DesHarnais. "Criteria for Selecting an Approach to Medical Service Area Definition," 23rd Public Health Conference on Records and Statistics, Public Health Service, Centers for Disease Control, National Center for Health Statistics, Washington, DC, July 17, 1991.

DesHarnais, S.I. and **Simpson, K.N.**, "Using Multiple Risk-Adjusted Indices to Compare Hospital's Performance," Twenty-Seventh International Hospital Congress, June 4, 1991, Washington, D.C., USA.

Simpson KN Analysis of Issues for Financial Survival, National Association of Community Health Centers, 21st Annual Convention, Cincinnati, Sept. 10, 1990.

Simpson K. and L. Snider, "Should Mammography Insurance Coverage be Legislated: Results of Meta Analysis, Computer Modeling, and Issue Analysis," Panel on Technology Assessment and Technological Change, Seventh Annual Meeting of the Association for Health Services Research, June 19, 1990.

Stoodt, G., and **K.N. Simpson**, "Data Based Interventions for Cancer Control." Paper presented at American Public Health Association, Chicago, 1989.

MacRae, Duncan, Jr. and **K. Simpson**, "The Uninsured Poor: Estimating Incidence in North Carolina Counties," N.C. Sociological Association, 1986.

Simpson, K. and T. Ricketts, "The Uninsured Poor in North Carolina: An Analysis of their Geographic Distribution and Inpatient Discharge Patterns," American Public Health Association, 1986.

Selected CE/Short Courses/Invited Presentations

Assessment of Infectious Disease Outcomes Research Studies. 6th Annual Anti-Infective Workshop. 4/26/02 Charleston SC.2003.

Piggy-back economic study designs: Focus on HIV trials. Faculty Seminar. Department of Biometry and Epidemiology. Medical University of South Carolina. November 12, 2001.

The US Pharmaceutical Industry. Medical University of South Carolina. Department of Health Administration and Policy. February 2000, July 2001, July 2002, Oct. 2003, July 2004.

Outcomes Research Designs for Urology. Medical University of South Carolina. Urology Residents Seminars. January 1999 and March 2001.

Health Economics and Outcomes Research. PhD Course. University of Copenhagen, Denmark March 10-13, 1998.

Use of Research Triangulation Methods to Assess Cost Effectiveness of Technologies and Guidelines. Australian Ministry of Family and Health Services. Canberra, Australia. Feb. 23, 1998.

Collecting economic data in IVD clinical trials. San Diego CA December, 1997.

Evidence-based Diagnostics. Australian Ministry of Family and Health Services. Canberra, Australia, November 1997.

Design of outcomes research in gastroenterology. Association for Outcomes Research in Gastroenterology and University of Chicago School of Medicine. September 23-25, 1997.

Cost of caring for patients with AIDS. Royal College of Medicine, London, England , Feb. 24, 1997.

Design of economic clinical trials in HIV+ disease. London, England, Feb. 26, 1997.

Planning for quality and outcomes in medical care delivery. MPH Course. School of Medicine, University of Portugal, Lisbon, Portugal. Feb. 17-29, 1997.

Methods for outcomes research in gastroenterology. Association for Outcomes Research in Gastroenterology and University of Chicago School of Medicine. August 23-25, 1996.

A Markov model for AIDS. European Community Concerted Action for AIDS, Economic Study Advisory Committee. June 4, 1996.

Advanced methods for modeling cost-effectiveness of pharmaceuticals. Second Annual CePOR Conference, UNC Chapel Hill NC. March 31, 1996.

Statistical issues in analyzing data from clinical trials. Symposium on Methodological and Statistical Issues of Quality-of-Life and Economic Evaluation in Cancer Clinical Trials. European Association for Research and Treatment of Cancer. Brussels, Belgium. Dec. 1-2, 1995.

Disease Management: Cost of Prevention vs. Treatment in HIV-Patients. Western Association of Directors of Medicaid Drug Programs. Santa Fe, NM. September 20, 1995.

Estimates of Annual Health Care Costs of HIV-Disease in the Florida Correctional System. Daytona Beach. September 25, 1995.

Measuring value-added by laboratory instruments: Comparing cost effectiveness of STAT testing. 19th Annual Conference. Clinical Laboratory Management Association. Minneapolis MN Aug. 27, 1995.

Cost and Consequences of Comprehensive Coverage for Ryan White Patients in North Carolina. North Carolina Dept. of Environment, Health and Natural Resources. Raleigh NC. Feb. 20, 1995.

Treatment protocols and utilization review in disease management. IMS America Client Conference. Palm Beach, Florida. May 24, 1995.

Use of Modeling in Pharmacoeconomic Analysis. Symposium on Standards for Pharmacoeconomics. Center for Cost and Outcomes Research, UNC Friday Center, Chapel Hill, NC. April 1-3, 1995.

How to document and improve quality of health care through effective outcomes analysis. Conference for Arab Health 95, Dubai UAE, Jan 25, 1995.

Technology Assessment of Prostate-specific Antigen Tests (PSA): A Case Study. Post-Conference Course on Assessment of Diagnostic Technology. Johns Hopkins University. Baltimore MD. June 22-25, 1994.

Pharmacoeconomics Course. Burroughs Wellcome Co. Research Triangle Park NC. Aug. 30 - Dec. 6, 1994.

Measurement and Modeling Outcomes for Economic Analysis of Medical Technologies. Office of Health Technology Assessment, AHCPR, Rockville M.D. April 12-13, 1993.

Update: 06/02/2008